Brought to you by 
Convergence spins out of GSK, gets $35.4mm in Series A round
29 Oct 2010
Executive Summary
New Leaf Ventures, Apposite Capital, and SV Life Sciences have equally invested in newly launched UK biotech Convergence Pharmaceuticals Ltd.'s $35.4mm Series A financing. Each of the backers is contributing a board member.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Spin-Off
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Convergence spins out of GSK, gets $35.4mm in Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice